SALINA ANDERSON: Open Payments
NPI 1629461140 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,233 in 69 payments from 16 companies in 2025. Trend: 2023 $512 · 2024 $809 · 2025 $1,233
Food & beverage: $1,233
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 11 | $161 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $157 |
| Vanda Pharmaceuticals Inc. | 7 | $141 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| Noven Therapeutics, LLC | 4 | $79 |
| Supernus Pharmaceuticals, Inc. | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Lundbeck LLC | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
Products named: ARISTADA, CAPLYTA, REXULTI, Auvelity, HETLIOZ, Xelstrym, Qelbree, Jornay PM.
Industry payments across NE — which companies pay providers there.
